On November 4, 2026, Hans van Houte, the Chief Financial Officer of Nurix Therapeutics, Inc., executed a sale of 4,769 shares of the company's common stock. This transaction is significant as it highlights the ongoing adjustments in executive stock holdings within the pharmaceutical sector.

Nurix Therapeutics, Inc. is a company engaged in the pharmaceutical preparations industry, specifically classified under the SIC code 2834. The company is based in Brisbane, California, and operates under the trading symbol NRIX on stock exchanges. Recent filings indicate that the company has been active in reporting various transactions related to its executives.

According to the SEC filing, van Houte sold 3,300 shares at a weighted average price of $15.38 and an additional 1,469 shares at a weighted average price of $16.20. The filing states, "This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person." Following these transactions, van Houte retains ownership of 42,745 shares.

This sale may affect various stakeholders, including shareholders and potential investors, as it reflects the executive's confidence in the company's future and financial health. Such transactions are closely monitored within the pharmaceutical industry, where executive trading can signal shifts in management strategy or company outlook.

The filing does not say what happens next.